United States - English - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - chloroquine phosphate (unii: 6e17k3343p) (chloroquine - unii:886u3h6uff) - chloroquine phosphate 500 mg - chloroquine phosphate tablets are indicated for the suppressive treatment and for acute attacks of malaria due to p. vivax, p.malariae, p. ovale , and susceptible strains of p. falciparum. the drug is also indicated for the treatment of extraintestinal amebiasis. chloroquine phosphate tablets does not prevent relapses in patients with vivax or malariae malaria because it is not effective against exoerythrocytic forms of the parasite, nor will it prevent vivax or malariae infection when administered as a prophylactic. it is highly effective as a suppressive agent in patients with vivax or malariae malaria, in terminating acute attacks, and significantly lengthening the interval between treatment and relapse. in patients with falciparum malaria it abolishes the acute attack and effects complete cure of the infection, unless due to a resistant strain of p. falciparum . use of this drug is contraindicated in the presence of retinal or visual field changes either attributable to 4-aminoquinoline compounds or to a

United States - English - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - chloroquine phosphate (unii: 6e17k3343p) (chloroquine - unii:886u3h6uff) - chloroquine phosphate 250 mg - chloroquine phosphate tablets are indicated for the suppressive treatment and for acute attacks of malaria due to p. vivax, p. malariae, p. ovale , and susceptible strains of p. falciparum. the drug is also indicated for the treatment of extraintestinal amebiasis. chloroquine phosphate tablets does not prevent relapses in patients with vivax or malariae malaria because it is not effective against exoerythrocytic forms of the parasite, nor will it prevent vivax or malariae infection when administered as a prophylactic. it is highly effective as a suppressive agent in patients with vivax or malariae malaria, in terminating acute attacks, and significantly lengthening the interval between treatment and relapse. in patients with falciparum malaria it abolishes the acute attack and effects complete cure of the infection, unless due to a resistant strain of p. falciparum . use of this drug is contraindicated in the presence of retinal or visual field changes either attributable to 4-aminoquinoline compounds

United States - English - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 5 mg - levocetirizine dihydrochloride tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. levocetirizine dihydrochloride tablets are indicated for the relief of symptoms associated with perennial allergic rhinitis in adults and children 6 years of age and older. levocetirizine dihydrochloride tablets are indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. the use of levocetirizine dihydrochloride is contraindicated in: patients with known hypersensitivity to levocetirizine or any of the ingredients of levocetirizine dihydrochloride tablets, or to cetirizine. observed reactions range from urticaria to anaphylaxis [see adverse reactions (6.2) ]. patients with end-stage renal disease (cl cr < 10 ml/min) and patients undergoing hemodialysis children 6 months to 11 years of age with impaired renal function pregnancy category b there are

United States - English - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - cefadroxil (unii: 280111g160) (cefadroxil anhydrous - unii:q525pa8jjb) - cefadroxil monohydrate, usp is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: urinary tract infections caused by e. coli, p. mirabilis, and klebsiella species. skin and skin structure infections caused by staphylococci and/or streptococci. pharyngitis and/or tonsillitis caused by streptococcus pyogenes (group a beta-hemolytic streptococci). note: only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. cefadroxil monohydrate is generally effective in the eradication of streptococci from the oropharynx. however, data establishing the efficacy of cefadroxil monohydrate for the prophylaxis of subsequent rheumatic fever are not available. note: culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated. to reduce the development of drug-resistant bacteria and maint

United States - English - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - tablet, film coated, extended release - 1000 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin extended-release tablets and other antibacterial drugs, clarithromycin extended-release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. the efficacy and safety of clarithromycin extended-release tablets in treating other infections for which other formulations of clarithromycin are approved have not been established. clarithromycin is contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibiotics. concomitant administration of clarithromycin and any of the following drugs is contraindicated: cisapride, p

United States - English - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - metoprolol tartrate (unii: w5s57y3a5l) (metoprolol - unii:geb06nhm23) - metoprolol tartrate 25 mg - hypertension metoprolol tartrate tablets are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive agents. angina pectoris metoprolol tartrate is indicated in the long-term treatment of angina pectoris. myocardial infarction metoprolol tartrate tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality when used alone or in conjunction with intravenous metoprolol tartrate. oral metoprolol tartrate therapy can be initiated after intravenous metoprolol tartrate therapy or, alternatively, oral treatment can begin within 3 to 10 days of the acute event (see dosage and administration, contraindications, and warnings). hypertension and angina metoprolol tartrate is contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure (see warnings). hypersensitivity to metoprolol tartrate and related d

United States - English - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - amoxicillin (unii: 804826j2hu) (amoxicillin - unii:804826j2hu), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - powder, for suspension - 200 mg in 5 ml - amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: lower respiratory tract infections - caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis . otitis media - caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis . sinusitis - caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis . skin and skin structure infections - caused by β-lactamase-producing strains of s. aureus , e. coli , and klebsiella spp. urinary tract infections - caused by β-lactamase-producing strains of e. coli , klebsiella spp. and enterobacter spp. while amoxicillin and clavulanate potassium is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with amoxicillin and clavulanate potassium due

United States - English - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - tablet, coated - 3.125 mg - carvedilol is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40% (with or without symptomatic heart failure) [see clinical studies (14.1)] . carvedilol is indicated for the management of essential. it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see drug interactions (7.2)] . carvedilol is contraindicated in the following conditions: - bronchial asthma or related bronchospastic conditions. deaths from status asthmaticus have been reported following single doses of carvedilol. - second- or third-degree av block - sick sinus syndrome - severe bradycardia (unless a permanent pacemaker is in place) - patients with cardiogenic shock or who have decompensated heart failure requiring the use of intravenous inotropic therapy. such patients should first be weaned from intravenous therapy before initiating carvedilol - p

United States - English - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 250 mg - clarithromycin tablets, usp and clarithromycin for oral suspension, usp are indicated for the treatment of mild to moderate infections caused by susceptible isolates of the designated bacteria in the conditions as listed below: adults (clarithromycin immediate-release tablets and clarithromycin for oral suspension) pharyngitis/tonsillitis due to streptococcus pyogenes (the usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. clarithromycin is generally effective in the eradication of s. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present). acute maxillary sinusitis due to haemophilus influenzae , moraxella catarrhalis, or streptococcus pneumoniae. acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae , haemophilus parainfluenzae

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cefaclor monohydrate 267.5mg equivalent to cefaclor 250 mg (plus 2% overage);  ; cefaclor monohydrate 267.5mg equivalent to cefaclor 250 mg (plus 2% overage) - capsule - 250 mg - active: cefaclor monohydrate 267.5mg equivalent to cefaclor 250 mg (plus 2% overage)   excipient: brilliant blue fcf carmoisine colloidal silicon dioxide croscarmellose sodium gelatin   magnesium stearate methyl hydroxybenzoate   ponceau 4r pregelatinised maize starch propyl hydroxybenzoate   titanium dioxide   water   active: cefaclor monohydrate 267.5mg equivalent to cefaclor 250 mg (plus 2% overage) excipient: brilliant blue fcf carmoisine colloidal silicon dioxide croscarmellose sodium gelatin   magnesium stearate methyl hydroxybenzoate   ponceau 4r pregelatinised maize starch propyl hydroxybenzoate   titanium dioxide   - · lower respiratory infections, including pneumonia caused by s. pneumoniae, h. influenzae (including both ampicillin-sensitive and ampicillin-resistant strains), and s. pyogenes (group a beta- haemolytic streptococci), m.catarrhalis, acute bronchitis, and acute exacerbations of chronic bronchitis. · upper respiratory infections, including pharyngitis and tonsillitis caused by s. pyogenes (group a beta-haemolytic streptococci) and m. catarrhalis. note: penicillin is the usual medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. amoxicillin has been recommended by the american heart association as the standard regimen for the prophylaxis of bacterial endocarditis for dental, oral, and upper respiratory tract procedures, with penicillin v a rational and acceptable alternative in the prophylaxis against beta-haemolytic streptococcal bacteriaemia in this setting. cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever or bacterial endocarditis are not available at present.